Evidence map›Paper›PMID 34266475›Full record

ArticleBMC pharmacology & toxicology2021

Exploring cardioprotective potential of esculetin against isoproterenol induced myocardial toxicity in rats: in vivo and in vitro evidence.

Chitikela P Pullaiah, Vinod K Nelson, Sushma Rayapu, Narasimha Kumar G V, Thyagaraju Kedam

Open access · goldAbstract read
In one paragraph

Article in BMC pharmacology & toxicology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 47 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. NMDA receptor modulation by Esculetin: Investigating behavioral, biochemical and neurochemical effects in schizophrenic mice model.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024
    Article
  10. Frontiers in pharmacology · 2024
    Article
  11. Article
  12. Article
  13. Review
  14. Sonicated Extract from the Aril ofJournal of toxicology · 2022
    Article
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Chitikela P PullaiahDepartment of Pharmacology, Siddha Central Research Institute, Central Council for Research in Siddha, Ministry of AYUSH, Govt of India, Chennai, 600106, India. samuelpharma@gmai.com.
Vinod K NelsonDepartment of Pharmacology & Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Hajipur, 844102, India. Vinod.kumar457@gmail.com.
Sushma RayapuDepartment of Pharmacology, Sri Padmavathi School of Pharmacy, Tirupati, 517503, India.
Narasimha Kumar G VDepartment of Pharmacology, Dr Anjali Chatterjee Regional Institute of Homeopathy, Kolkata, 700035, India.
Thyagaraju KedamDepartment of Biochemistry and College of Pharmaceutical Sciences, S V University, Tirupati, 517502, India.
Central Council for Research in Siddha · INNational Institute of Pharmaceutical Education and Research · INSri Padmavati Mahila Visvavidyalayam · INSri Venkateswara University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEsculetin is a natural coumarin derivative from various plants with multiple pharmacological effects. Hence, the present study was undertaken to explore the cardio protective potential of esculetin against isoproterenol induced myocardial toxicity in rats.

methodsThe treatment schedule was fixed for 28 days and the rats were divided into five groups of six each. Rats of group I received the normal saline and served as normal control, group II was received ISO (100 mg/kg body weight) for last two consecutive days of the study and served as disease control. Groups III and IV received esculetin 10 and 20 mg/kg body weight respectively once a day per oral for 28 days along with ISO for last two consecutive days of the study. Cardiac biomarkers such as CK-MB and LDH, membrane bound Na+ /K+ ATPases activity, myocardial lysosomal enzymes activity and tissue antioxidants status were estimated in the heart tissue samples. The histopathological changes in the myocardium were also assessed. Further, DPPH assay was done to evaluate the free radicals scavenging potential of esculetin. Cytoxicity assay, intracellular ROS levels by DCFDA assay and m-RNA expression of TNF-α, IL-6 and NF-κB by quantitative RT-PCR in H9c2 cell lines.

resultsThe increased levels of CK-MB, LDH, LPO, myocardial lysosomal enzymes and membrane bound Na+ /K+ ATPase levels by ISO administration was significantly increased with concomitant decrease in tissue antioxidant enzymes such as GSH, Catalase, and SOD. Pre-treatment with esculetin for 28 days has significantly decreased the levels of cardiac bio-markers, lysosomal enzymes, membrane bound Na+ /K+ ATPase levels as well as Lipid peroxides which is in contrary to the ISO group. Amelioration of the antioxidant levels were also found in esculetin treated groups. Histopathological examination of heart reveals that myocardial degeneration, mononuclear cell infiltration was noticed in ISO treated rats, whereas the same was restored with esculetin treatment. In H9C2 cell lines esculetin could effectively reduced intracellular ROS inhibition and m-RNA expression of pro-inflammatory cytokines including TNF-α, IL-6 and NF-κB to prevent apoptosis or cell necrosis.

conclusionThe study provides the evidence of cardioprotective potentials of esculetin against isoproterenol induced myocardial infarction by antioxidant and myocardial membrane stabilization along with in vitro protection from arsenic induced ROS cell necrosis or apoptosis in H9C2 cells.

Indexed as

Adrenergic beta-AgonistsAnimalsArsenicBiphenyl CompoundsCardiotonic AgentsCell LineCell SurvivalCytokinesIsoproterenolLysosomesMaleMyocardial InfarctionMyocardiumPicratesRatsRats, Wistar1,1-diphenyl-2-picrylhydrazylAdrenergic beta-AgonistsArsenicBiphenyl CompoundsCardiotonic AgentsCytokinesesculetinIsoproterenolPicratesReactive Oxygen SpeciesSodium-Potassium-Exchanging ATPaseUmbelliferonesAntioxidantCardioprotectionEsculetinIsoproterenolLysosomesOxidative stress

Identifiers

PMID34266475
PMCPMC8281642
OpenAlexW3136311408

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.